Holen Sie sich die Stockscreener-App
17.50
0.17%
-0.03
Handel nachbörslich:
17.85
0.35
+2.00%
Schlusskurs vom Vortag:
$17.53
Offen:
$17.54
24-Stunden-Volumen:
1.05M
Relative Volume:
0.95
Marktkapitalisierung:
$1.81B
Einnahmen:
$71.78M
Nettoeinkommen (Verlust:
$-295.28M
KGV:
-5.5385
EPS:
-3.1597
Netto-Cashflow:
$-271.85M
1W Leistung:
+10.38%
1M Leistung:
+5.23%
6M Leistung:
+4.42%
1J Leistung:
+75.18%
1-Tages-Spanne:
$17.32
$17.85
1-Wochen-Bereich:
$15.07
$17.85
52-Wochen-Spanne:
$8.195
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
17.50 | 1.81B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics stock (US67079U1007): clinical pipeline and market reaction under the microscope - AD HOC NEWS
Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
NRIX Reiterated by BTIG -- Price Target Maintained at $30 - GuruFocus
Nurix Therapeutics (NRIX) moves 6.9% higher: Will this strength last? - MSN
A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection - simplywall.st
Which Is a Better Investment, Kymera Therapeutics, Inc. or Nurix Therapeutics, Inc. Stock? - AAII
Nurix Therapeutics' (NRIX) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Nurix Therapeutics : NRIX - 24/7 Wall St.
Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG - Moomoo
Nurix Therapeutics (NRIX) director awarded 31,250 stock options at $15.86 strike - Stock Titan
Nurix (NRIX) director granted stock options on 31,250 common shares - Stock Titan
Nurix Therapeutics (NRIX) director receives 31,250-share stock option grant - Stock Titan
Nurix Therapeutics (NRIX) director receives grant of 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director granted 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director gets 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director awarded 31,250 stock options - Stock Titan
Nurix Therapeutics Shareholders Back Directors and Governance Proposals - TipRanks
Vestal Point (NRIX) discloses 6.5M-share stake, 6.3% of float - Stock Titan
Nurix Therapeutics (NRIX) shareholders approve directors, PwC audit and say-on-pay - Stock Titan
Nurix Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) — 6.35M shares - Stock Titan
Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU - Traders Union
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting - Investing News Network
Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative? - simplywall.st
Experimental hives pill from Nurix shows 25x lab potency vs remibrutinib - Stock Titan
(NRIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Nurix Therapeutics stock (US67079U1007): Analysts see 144% upside potential - AD HOC NEWS
Nurix Therapeutics, Inc.Common stock (NQ: NRIX - FinancialContent
Nurix stock delivers 64% return after Fair Value identified opportunity By Investing.com - Investing.com Australia
Is Nurix Therapeutics (NRIX) Stock’s Premium P/S Multiple Fair After Recent Mixed Share Price Performance - Yahoo Finance
Nurix stock delivers 64% return after Fair Value identified opportunity - Investing.com
How Investors Are Reacting To Nurix Therapeutics (NRIX) Securing EHA Oral Slot For BTK Degrader Data - Yahoo Finance
Nurix Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Vanguard Group Inc. Purchases 1,460,736 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix CEO to speak at two May–June healthcare investor events - Stock Titan
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress - The Manila Times
Nurix Therapeutics Announces Bexobrutideg Oral Presentation - TradingView
Nurix Therapeutics to present new Phase 1a b data on BTK degrader NX-5948 in CLL at EHA2026 - Traders Union
TradingKey - TradingKey
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Move - Sahm
Nurix Therapeutics stock (US67079U1007): Biotech firm trading with deep losses and cash cushion - AD HOC NEWS
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 - Yahoo Finance
Number of shareholders of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
FMR LLC Boosts Position in Nurix (NRIX) — 5.54M Shares Reported - Stock Titan
Nurix CFO Hans van Houte sells $233k in company stock - Investing.com Canada
Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NRIX) CFO sells 14,055 shares in planned trade - Stock Titan
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
[144] Nurix Therapeutics, Inc. SEC Filing - Stock Titan
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):